English
Regional settings| Spread | 0.60 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022091% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000132% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Germany | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 149.45 |
| Open | 149.15 |
| 1-Year Change | -7.79% |
| Day's Range | 147.8 - 149.7 |
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
BRIEF: For the fiscal year ended 31 December 2021, Merck KGaA revenues increased 12% to EUR19.69B. Net income applicable to common stockholders increased 54% to EUR3.06B. Revenues reflect Life Science segment increase of 20% to EUR8.99B, Healthcare segment increase of 7% to EUR7.09B, United States (Country) segment increase of 13% to EUR5.25B, Rest of Europe segment increase of 14% to EUR4.03B.
2003 Q1 has been restated to reflect discontinued operations. 01/2007, Rights Issue, 4 new shares for every 29 shares held @ EUR 78 (Factor: 1.015602). 6/2014, 2-for-1 stock split (Factor: 2).
